Efficacy of Targeted Therapy in Genetic Subtypes of Aggressive Lymphoma – Module 3

Released On
March 10, 2022

Expires On
March 9, 2023

Media Type
Internet

Completion Time
30 minutes

Specialty
Hematology-Oncology, Primary Care

Topic(s)
Lymphoma, Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

Funding provided by The Leukemia & Lymphoma Society. No commercial support provided for this accredited continuing education activity.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Program Overview

This activity provides an overview of molecular and clinical subtypes of lymphoma and the mechanisms by which targeted therapies work for molecular subtypes.

Learning Objective

Upon completion of this activity, participants should be better able to:

  • Summarize the efficacy of targeted therapy in genetic subtypes of aggressive lymphoma.

 

Faculty

FACULTY_NAME

Louis M. Staudt, MD, PhD

Chief, Lymphoid Malignancies Branch
Director, Center for Cancer Genomics
National Cancer Institute
Bethesda, MD

 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Louis M. Staudt, MD, PhD, has no relevant financial relationship(s) with ineligible companies to disclose.

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

The Leukemia & Lymphoma Society planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Instructions for Participation and Credit

In order to receive credit, users must:
  • Read the learning objectives and faculty disclosure
  • Participate in the activity
  • Complete the activity evaluation

A statement of credit will be available to print immediately. There is no fee to participate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information

If you have questions about this activity, please contact RMEI at contact@rmei.com.